altinicline

(redirected from SIB-1508Y)

altinicline

An alpha-4, beta-2 nicotinic acetylcholine receptor agonist which stimulates dopamine and acetylcholine release in the brain. Altinicline was being developed for managing motor, affective and cognitive changes of Parkinson's disease, but failed in phase-2 clinical trials.
References in periodicals archive ?
These risks and uncertainties include SIBIA's reliance on corporate partnerships and ability to enter into new corporate partnerships, whether SIBIA will be successful in demonstrating the safety and efficacy of SIB-1508Y and SIB-1553A in humans, whether SIBIA will be able to meet its development goals with respect to its drug candidates and proprietary targets, SIBIA's early stage of development, the new and uncertain state of SIBIA's technologies, SIBIA's future capital needs and the uncertainty of receiving additional funding, uncertainties regarding patents, proprietary rights and regulatory matters, whether the transactions contemplated by the merger agreement between SIBIA and Merck & Co.
Nasdaq: SIBI) today announced results from two initial Phase 2 clinical trials of SIB-1508Y (altinicline) in Parkinson's disease (PD) patients.
Lilly will conduct and fund all clinical trials for compounds discovered during the project and will receive an exclusive option to SIBIA's two clinical candidates, SIB-1508Y for Parkinson's disease and SIB-1553A for Alzheimer's disease, both currently in phase II trials.
These risks and uncertainties include SIBIA's ongoing litigation with Cadus, uncertainties regarding appeals and related proceedings, the companies' technologies, uncertainties regarding the company's SIB-1508Y and SIB-1553A compounds, the risk that further development of such compounds will be unsuccessful or terminated, the risk that Lilly will not exercise its options to acquire rights to such compounds, the risk that SIBIA may never receive any milestone or royalty revenue from such compounds or any other compound, uncertainties regarding SIBIA's future capital needs and the uncertainty of receiving additional funding, and other research, development and market risks.
Research and development expenses for the first quarter ended March 31, 1999 decreased to $4,502,000 from $4,796,000 for the corresponding period in 1998 due primarily to decreases in clinical and non-clinical costs related to the development of SIB-1508Y, SIBIA's lead compound for Parkinson's disease, and SIB-1553A, SIBIA's lead compound for Alzheimer's disease; however, research costs increased related to expanded drug discovery programs for chronic pain, apoptosis, psychiatric disorders and neuroprotection.
for development of SIB-1508Y, SIBIA's lead compound for Parkinson's disease, and to the completion of the research support phase of collaborations with Eli Lilly & Company and Novartis AG in October 1997 and September 1998, respectively.
This is a double-blind, randomized, placebo controlled, crossover study measuring safety, tolerability and efficacy of SIB-1508Y in mid-to-late-stage Parkinson's patients who will also receive half their usual dose of L-DOPA.
for development of SIB-1508Y, SIBIA's lead compound for Parkinson's disease and the completion of the research support phase of the collaboration with Eli Lilly & Company.
Nasdaq: SIBI) reported that preclinical studies of SIB-1508Y, one of the Company's proprietary neuronal nicotinic acetylcholine receptor (nAChR) agonists, and currently in Phase 2 clinical trials, has shown the ability to substantially protect neurons from degenerative changes in a rodent model of Parkinson's disease.
Meiji") for the development of SIB-1508Y, SIBIA's lead compound for Parkinson's disease.
Expenses for the first quarter of 1998 were higher due primarily to an increase in research and development expenses associated with Phase 2 clinical trials of SIB-1508Y in Parkinson's patients, continued pre-clinical development of SIB-1553A, currently in development for Alzheimer's disease, and expanded programs in drug discovery.
SIB-1508Y is a selective brain cholinergic agonist which is being developed as a novel therapeutic agent to treat the motor, cognitive and affective deficits in Parkinson's disease.